[144] KIMCO REALTY CORP SEC Filing
Form 144 notice by an insider of Kimco Realty Corp (KIM) proposes the sale of 23,100 shares of common stock through Wells Fargo Clearing Services on or about 09/29/2025 with an aggregate market value of $500,142.95. The shares were acquired as annual grants from the issuer on 02/13/2022 and were fully paid on that date. The filing reports 677,200,477 shares outstanding, and states there were no securities sold by the reporting person in the prior three months. The signer represents they are not aware of undisclosed material adverse information about the issuer.
- Clear compliance disclosure of proposed sale including broker, date, and aggregate value
- Securities were acquired as annual grants, indicating a routine vested-compensation source
- No sales by the reporting person in the prior three months, suggesting limited recent insider dispositions
- Proposed insider sale of 23,100 shares represents a cash exit of company stock (though immaterial relative to outstanding shares)
Insights
TL;DR: Small, routine insider sale notice; likely procedural compliance rather than a material event.
The filing documents a planned sale of 23,100 shares valued at about $500k, representing roughly 0.0034% of the outstanding shares (23,100 of 677,200,477). The shares were granted by the issuer and acquired in 2022, indicating this is an exit of vested compensation rather than a market-moving disposition. The absence of any sales in the prior three months and the standard certification regarding undisclosed material information support a compliance-focused filing. No earnings or operational data are provided.
TL;DR: Filing meets Rule 144 disclosure requirements; procedural and transparent, with no material governance red flags shown.
The notice identifies the broker, anticipated sale date, acquisition method (annual grants), and payment details, fulfilling disclosure norms. Because the position size relative to shares outstanding is negligible and there are no recent related sales, this does not indicate concentration risk or unusual insider activity. The mandatory attestation about material adverse information is present, and no additional remarks or complexities are included.